In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab June 10, 2022Vol.48 No.23By Alice Tracey
Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing April 29, 2022Vol.48 No.17By Alice Tracey
Trials & Tribulations Here’s how we can make clinical trials more inclusive February 11, 2022Vol.48 No.06By Jenny Sherak
Trials & Tribulations Leveraging cutting-edge technology to address the impact of COVID-19 on cancer screening, diagnosis, and treatment February 04, 2022Vol.48 No.05By Gustaf Salford
Trials & Tribulations Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease November 12, 2021Vol.47 No.42By Fred R. Hirsch
FreeTrials & Tribulations No longer “experimental”—Prostate cancer patients should have access to proton therapy November 05, 2021Vol.47 No.41By Shaakir Hasan
Trials & Tribulations Removing barriers to cancer care in underserved communities October 29, 2021Vol.47 No.40By Dany Habr
Trials & Tribulations A FLASH flood of research relating to ultra-high dose rate radiation therapy October 22, 2021Vol.47 No.39By Constantinos Koumenis and Amit Maity
Trials & Tribulations Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials September 10, 2021Vol.47 No.33By Yu Shyr
